AllSci News
Annovis Bio closes USD 10m offering to fund Phase III Alzheimer's disease trial
Annovis Bio, Inc. (NYSE: ANVS), a Malvern, Pennsylvania-based clinical-stage company developing oral therapies for neurodegenerative disease, has closed a...
IASO Bio partners with Instituto Butantan on CAR-T cell therapy licensing for Brazil
IASO Biotechnology, headquartered in Shanghai and Nanjing, China, with US operations in Pleasanton, California, has signed a technology licensing agreement with Instituto…
Sino-US biotech Vivatides closes USD 54m Series A for extrahepatic RNA therapeutics
Vivatides Therapeutics, a biotechnology company with operations in Woburn, Massachusetts and Suzhou, China focused on extrahepatic RNA-targeting...
MacroGenics' lorigerlimab resumes Phase II enrollment for gynecologic cancers after FDA hold lifted
MacroGenics, the Rockville, Maryland-based biopharmaceutical company, announced on April 8, 2026 that the US FDA has removed a partial clinical hold on the...
BeOne takes first China approval for Amgen BsAb tarlatamab in ESCLC
BeOne Medicines (Nasdaq: ONC; formerly BeiGene) announced that tarlatamab, a DLL3/CD3-targeting bispecific T-cell engager (TCE) co-developed with Amgen, has received conditional approval…
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access
Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at…
CMS advances INHBE-targeting siRNA into first-in-human obesity study
China Medical System Holdings (HKEX: 00867), a Shenzhen-based specialty pharmaceutical company historically known for in-licensing and commercialising drugs...
Zentalis' azenosertib advances in cyclin E1-positive platinum-resistant ovarian cancer trial
Zentalis Pharmaceuticals announced on April 9 that a prespecified interim analysis from Part 2a of the DENALI trial has identified 400mg once daily on a...
Avalyn Pharma files for Nasdaq IPO to advance inhaled pulmonary fibrosis therapies
Avalyn Pharma Inc. filed for an initial public offering on the Nasdaq Global Market under the ticker symbol AVLN, according to an S-1 registration statement...
China's Oricell closes USD 110 million pre-IPO financing for CAR-T pipeline
Shanghai-based Oricell Therapeutics Holdings Limited has closed a pre-IPO financing round in excess of USD 110 million to advance its CAR-T cell therapy...
Emalex Biosciences receives US patent for orally disintegrating ecopipam tablet formulation
Emalex Biosciences (USA) received a US Patent and Trademark Office grant covering an orally disintegrating tablet formulation of ecopipam, a selective dopamine…
Imagene AI and Daiichi Sankyo collaborate on multimodal biomarker discovery for ADC development
Imagene AI (Nasdaq: IMA), a Miami-based precision oncology AI company, announced a collaboration with Japan-based Daiichi Sankyo (TSE: 4568) to apply Imagene’s…
Sunho's ISH0613 bispecific antibody enters Phase Ia for systemic lupus erythematosus
SUNHO (China) BioPharmaceutical has registered a Phase Ia first-in-human clinical trial for ISH0613, an internally developed bifunctional bispecific...
Click Therapeutics closes USD 50m Series D led by Boehringer for prescription digital device
New York-based Click Therapeutics has closed a Series D round anchored by a USD 50 million strategic investment from Boehringer Ingelheim, alongside...
C4 Therapeutics, Roche expand partnership on degrader-antibody conjugates in USD 1b+ deal
C4 Therapeutics, Inc. (Nasdaq: CCCC), a Watertown, Massachusetts-based clinical-stage biopharmaceutical company, has entered into a new collaboration agreement with Roche (SIX: RO,…
The AllSci Brief
Systematic R&D and deal news. Daily.